Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673231 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,240
- Enrollment target
- 20
- Study locations
NCT00673231 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 1,240 participants, above the 1,098-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00673231, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Study Locations (20)
Other
- Research Site - Salzburg
- Research Site - Vienna
- Research Site - Pleven
- Research Site - Rousse
- Research Site - Sofia
- Research Site - Varna
California
- Research Site - Fresno
- Research Site - Greenbrae
Illinois
- Research Site - Chicago
- Research Site - Springfield
Texas
- Research Site - Corpus Christi
- Research Site - Dallas
Virginia
- Research Site - Norfolk
- Research Site - Richmond
Georgia
- Research Site - Roswell
Indiana
- Research Site - Indianapolis
Nebraska
- Research Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,240 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673231
The ClinicalTrials.gov registry entry for NCT00673231 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,098-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (13% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00673231 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00673231 about?
NCT00673231 is a clinical study titled "Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin". This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
What is the current status of trial NCT00673231?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,240 participants. The study started on 2008-04. Estimated completion is 2011-01.
What conditions does trial NCT00673231 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00673231?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00673231?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00673231 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.